Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PER2 | O15055 | 2/20 | 0.38 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.35 |
| ▸ | AOC2 | O75106 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | S100A4 | P26447 | 1/20 | 0.32 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.32 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22833746 | 0.89 | TSHR (0.51) | TSHRAPEX1BLMPER2CRY2 | |
| SCHEMBL7386709 | 0.84 | TSHR (0.44) | TSHRAPEX1BLMOPRM1OPRL1 | |
| SCHEMBL15438497 | 0.83 | KMT2A (0.42) | PER2CRY2AOC2KDM4EPOLB | |
| SCHEMBL27517863 | 0.81 | TSHR (0.44) | TSHRAPEX1BLMOPRM1OPRL1 | |
| SCHEMBL2617915 | 0.80 | TSHR (0.41) | TSHRAPEX1BLMOPRM1OPRL1 | |
| SCHEMBL3716092 | 0.79 | PER2 (0.36) | PER2CRY2OPRM1OPRL1AOC2 | |
| SCHEMBL22855955 | 0.76 | TSHR (0.38) | TSHRAPEX1BLMOPRM1OPRL1 | |
| SCHEMBL3548171 | 0.75 | TSHR (0.43) | TSHRAPEX1BLMOPRM1OPRL1 | |
| SCHEMBL16703117 | 0.74 | PER2 (0.39) | PER2CRY2OPRM1OPRL1AOC2 | |
| SCHEMBL21389132 | 0.73 | PER2 (0.40) | BLMPER2CRY2OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1272841-A | Novel lactam metalloprotease inhibitors | DU PONT PHARM CO (US) | 2000-11-08 | — | — | CN | claimed |
| US-9399033-B2 | Oligomer-containing pyrrolidine compounds | NEKTAR THERAPEUTICS (US) | 2016-07-26 | — | — | US | disclosed |
| US-20150366842-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS | 2015-12-24 | — | — | US | disclosed |
| US-9096517-B2 | Oligomer-containing pyrrolidine compounds | NEKTAR THERAPEUTICS (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096517-B2 | Oligomer-containing pyrrolidine compounds | NEKTAR THERAPEUTICS (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140288315-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS | 2014-09-25 | — | — | US | disclosed |
| US-20140288315-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS | 2014-09-25 | — | — | US | disclosed |
| US-8785661-B2 | Oligome-containing pyrrolidine compounds | NEKTAR THERAPEUTICS (US) | 2014-07-22 | — | — | US | disclosed |
| WO-2010132693-A2 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132693-A2 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2010-11-18 | — | — | WO | disclosed |
| CN-1272841-A | Novel lactam metalloprotease inhibitors | DU PONT PHARM CO (US) | 2000-11-08 | — | — | CN | disclosed |
| CN-1268111-A | Iodopropagylamine compounds, and industrial antimicrobial and antifungal agents, algicides, and antifouling agents containing the same | NISSAN CHEMICAL IND LTD (JP) | 2000-09-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366842-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | HTT, PML, NOD2 | TSHR 4577/4885APEX1 254/4885BLM 1932/4885 |
| US-20140288315-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | HTT, PML, NOD2 | TSHR 4577/4885APEX1 254/4885BLM 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.